Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26

Gastrin‐releasing peptide receptors (GRPRs) are overexpressed in prostate cancer and are suitable for targeted radionuclide therapy (TRT). We optimized the bombesin‐derived GRPR‐antagonist PEG(2)‐RM26 for labeling with (177)Lu and further determined the effect of treatment with (177)Lu‐labeled pepti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitran, Bogdan, Rinne, Sara S., Konijnenberg, Mark W., Maina, Theodosia, Nock, Berthold A., Altai, Mohamed, Vorobyeva, Anzhelika, Larhed, Mats, Tolmachev, Vladimir, de Jong, Marion, Rosenström, Ulrika, Orlova, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852655/
https://www.ncbi.nlm.nih.gov/pubmed/31077356
http://dx.doi.org/10.1002/ijc.32401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852655/
https://www.ncbi.nlm.nih.gov/pubmed/31077356
http://dx.doi.org/10.1002/ijc.32401

Ejemplares similares